Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment | Zendy

LiChun Lu | Zendy; YiHsuan Lee | Zendy; ChunJung Chang | Zendy; ChiaTung Shun | Zendy; ChihYeu Fang | Zendy; YuYun Shao | Zendy; TsungHao Liu | Zendy; AnnLii Cheng | Zendy; ChihHung Hsu | Zendy

Open Access

Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment

Author(s) -

LiChun Lu,

YiHsuan Lee,

ChunJung Chang,

ChiaTung Shun,

ChihYeu Fang,

YuYun Shao,

TsungHao Liu,

AnnLii Cheng,

ChihHung Hsu

Publication year - 2018

Publication title -

liver cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.916

H-Index - 34

eISSN - 2235-1795

pISSN - 1664-5553

DOI - 10.1159/000489021

Subject(s) - sorafenib , hepatocellular carcinoma , immunohistochemistry , medicine , immune system , pd l1 , oncology , cancer research , pathology , immunotherapy , immunology , cancer

Programmed death-ligand 1 (PD-L1) expression in the tumor microenvironment (TME) has been reported to be related to prognosis in patients with hepatocellular carcinoma (HCC) after hepatectomy. The impact of sorafenib on PD-L1 expression in the TME of advanced HCC is unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research